top of page
The Professional Network for Healthcare Experts
AbbVie licenses Nxera oral inflammatory bowel disease drug in agreement worth up to $1.47 billion
AbbVie has secured exclusive worldwide rights to Nxera Pharma's investigational oral EP4 receptor agonist NXE0033744 for inflammatory bowel disease in a licensing agreement potentially worth $1.47 billion.
nuaxia
6 days ago2 min read
FDA approves at-home subcutaneous Skyrizi induction for adults with Crohn's disease
The FDA has approved an at-home subcutaneous induction regimen for AbbVie's Skyrizi in Crohn's disease, offering an alternative to intravenous treatment initiation.
nuaxia
Oct 272 min read
AbbVie and Iambic enter AI-driven drug discovery collaboration across immunology, neuroscience and oncology
AbbVie and Iambic have entered a multi-year collaboration to use artificial intelligence and computational drug discovery across immunology, neuroscience and oncology.
nuaxia
Sep 222 min read
bottom of page